论文部分内容阅读
目的探讨ILK在早期肝病、肝硬化及肝细胞癌中的表达及临床病理意义。方法采用免疫组化技术(S-P法)检测ILK在103例早期肝病、肝硬化和肝细胞癌中的表达。结果 ILK在早期肝病、肝硬化和肝细胞癌中的表达阳性率呈明显递增趋势。各级肝病、肝硬化与肝细胞癌相比ILK的表达率差异具有显著性(P<0.05),且ILK表达率与肝细胞癌肿瘤大小及病理分级有关(P<0.05)。结论ILK可作为反映肝细胞增生病变程度及生物学行为的指标,对肝细胞增生与癌变的诊断及鉴别有参考价值。
Objective To investigate the expression of ILK in early liver disease, cirrhosis and hepatocellular carcinoma and its clinicopathological significance. Methods The expression of ILK in 103 cases of early liver disease, cirrhosis and hepatocellular carcinoma was detected by immunohistochemistry (S-P method). Results The positive rate of ILK in early liver disease, cirrhosis and hepatocellular carcinoma showed a significant positive trend. The expression rates of ILK in all kinds of liver diseases, liver cirrhosis and hepatocellular carcinoma were significantly different (P <0.05), and the expression of ILK was related to the size and pathological grade of hepatocellular carcinoma (P <0.05). Conclusion ILK can be used as an index to reflect the degree of hepatocellular hyperplasia and biological behavior, and has reference value for the diagnosis and identification of hepatocellular proliferation and carcinogenesis.